Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”

Introduction. Currently, clinical trials (CT) remain the only technology, which provides proof of efficacy and safety of new drugs and their subsequent release to the market. Medical researcher and informed consent (IC) are the main (and often the only) source of information for the patient about th...

Full description

Saved in:
Bibliographic Details
Main Authors: O. I. Zvonareva, E. S. Kulikov, I. A. Deev, O. S. Kobyakova, O. S. Fedorova, N. A. Kirillova, E. A. Starovoytova, N. G. Zhukova, I. A. Zhukova, V. V. Esip, E. D. Schastnyy, N. V. Khurkhurova, L. Yu. Nikitina, T. S. Golosova, I. D. Pimenov, M. A. Netaeva, S. V. Fedosenko
Format: Article
Language:English
Published: Siberian State Medical University (Tomsk) 2016-10-01
Series:Бюллетень сибирской медицины
Subjects:
Online Access:https://bulletin.ssmu.ru/jour/article/view/663
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839570017139556352
author O. I. Zvonareva
E. S. Kulikov
I. A. Deev
O. S. Kobyakova
O. S. Fedorova
N. A. Kirillova
E. A. Starovoytova
N. G. Zhukova
I. A. Zhukova
V. V. Esip
E. D. Schastnyy
N. V. Khurkhurova
L. Yu. Nikitina
T. S. Golosova
I. D. Pimenov
M. A. Netaeva
S. V. Fedosenko
author_facet O. I. Zvonareva
E. S. Kulikov
I. A. Deev
O. S. Kobyakova
O. S. Fedorova
N. A. Kirillova
E. A. Starovoytova
N. G. Zhukova
I. A. Zhukova
V. V. Esip
E. D. Schastnyy
N. V. Khurkhurova
L. Yu. Nikitina
T. S. Golosova
I. D. Pimenov
M. A. Netaeva
S. V. Fedosenko
author_sort O. I. Zvonareva
collection DOAJ
description Introduction. Currently, clinical trials (CT) remain the only technology, which provides proof of efficacy and safety of new drugs and their subsequent release to the market. Medical researcher and informed consent (IC) are the main (and often the only) source of information for the patient about the upcoming clinical trials, and thus have a direct impact on the perception of clinical trials, and on the patient’s decision about participation. However, the degree of influence of these factors on the clinical trials participants still remains unclear.Materials and methods. A multicenter cross-sectional study was conducted in different cities of the Russian Federation. Patients who had previous experience in CTs (or were enrolled in a CT at the time of this study) were asked to complete a questionnaire.Results. To assess the impact of researcher, all respondents were divided into 2 groups: patients that acquainted with IC in collaboration with the researcher, and the other group, which reviewed IC form independently. We evaluated the importance of the factors influencing the decision-making process on participation in clinical trials. According to our data, the most important factors were professional monitoring services (3,72 ± 1,00), regular condition monitoring (3,66 ± 0,98), and better medical care (3,62 ± 1,00). These factors were evaluated at significantly lower score by group of patients that acquainted with IC together with the researcher (3,55 ±0,94, vs 4,01 ± 0,90, p = 0,002; 3,52 ± 1,01 vs 3,87 ± 0,90, p = 0,040; 3,49 ± 0,94, vs 3,83 ± 1,06, p = 0,020 respectively). In assessing the factors that had negative impact on the interest in participating in a clinical trial, the most significant were risk of side effects (3,01 ± 1,27), study of new medication (2,68 ± 1,21), and the risk of getting into the placebo group (2,64 ± 1,34) (so-called “objective” risk factors). At the same time, risk of side effects and risk of getting into the placebo group were also assessed at significantly lower score by group of patients that acquainted with IC together with the researcher (2,87 ± 1,28, vs 3,33 ± 1,17, p = 0,024; 2,51 ±1,25, vs 3,03 ± 1,34, p = 0,022 respectively). Furthermore, it was found that in the case of the researcher’s assistance acquaintance time with IC reduced threefold. We also evaluated the effect of the complexity of IC text on the decision-making process on participation in clinical trials. The group of respondents, who rated the IC as easy, appeared to be more interested in the final results of the study.Conclusion. Thus, when assessing the impact of the researcher on the review process of informed consent with the decision to participate in clinical trials, we found that in the case of assistance of the researcher, the acquaintance time with IC is reduced three times. In addition, this group of patients during the conversation with the researcher shows better and more clear understanding of the nature and general methodology of clinical trials, resulting in an adequate assessment “objective” risk factors for participation in clinical trials. Thus, this group of patients is more informed, compared with an “independent” group. According to the study “Face to Face”, we can recommend mandatory participation of a researcher during review process of the IC.
format Article
id doaj-art-460c20e96e9a4c0aa94d31a4c3c9eb6a
institution Matheson Library
issn 1682-0363
1819-3684
language English
publishDate 2016-10-01
publisher Siberian State Medical University (Tomsk)
record_format Article
series Бюллетень сибирской медицины
spelling doaj-art-460c20e96e9a4c0aa94d31a4c3c9eb6a2025-08-04T16:45:39ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842016-10-01154405110.20538/1682-0363-2016-4-40-51582Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”O. I. Zvonareva0E. S. Kulikov1I. A. Deev2O. S. Kobyakova3O. S. Fedorova4N. A. Kirillova5E. A. Starovoytova6N. G. Zhukova7I. A. Zhukova8V. V. Esip9E. D. Schastnyy10N. V. Khurkhurova11L. Yu. Nikitina12T. S. Golosova13I. D. Pimenov14M. A. Netaeva15S. V. Fedosenko16Maastricht University Postbus 616, Maastricht Limburg 6200 MD, NetherlandsSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSaint-Petersburg State Budget Healthcare Institution “Consultative-Diagnostic Center № 85” 89/3, Av. Veteranov, Saint-Petersburg, 198260, Russian FederationMental Health Research Institute 4, Aleutskaya St., Tomsk, 634014, Russian FederationState budgetary institution of healthcare of Stavropol region “City hospital № 2” of Pyatigorsk 6, Admiralskogo, Pyatigorsk, 357538, Russian FederationKhanty-Mansiysk State Medical Academy 4, Mira St., Khanty-Mansiysk, 628011, Russian FederationNovokuznetsk Municipal Children Hospital 4 33, Dimitrova St., Novokuznetsk, 654063, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationSiberian State Medical University 2, Moskow Tract, Tomsk, 634050, Russian FederationIntroduction. Currently, clinical trials (CT) remain the only technology, which provides proof of efficacy and safety of new drugs and their subsequent release to the market. Medical researcher and informed consent (IC) are the main (and often the only) source of information for the patient about the upcoming clinical trials, and thus have a direct impact on the perception of clinical trials, and on the patient’s decision about participation. However, the degree of influence of these factors on the clinical trials participants still remains unclear.Materials and methods. A multicenter cross-sectional study was conducted in different cities of the Russian Federation. Patients who had previous experience in CTs (or were enrolled in a CT at the time of this study) were asked to complete a questionnaire.Results. To assess the impact of researcher, all respondents were divided into 2 groups: patients that acquainted with IC in collaboration with the researcher, and the other group, which reviewed IC form independently. We evaluated the importance of the factors influencing the decision-making process on participation in clinical trials. According to our data, the most important factors were professional monitoring services (3,72 ± 1,00), regular condition monitoring (3,66 ± 0,98), and better medical care (3,62 ± 1,00). These factors were evaluated at significantly lower score by group of patients that acquainted with IC together with the researcher (3,55 ±0,94, vs 4,01 ± 0,90, p = 0,002; 3,52 ± 1,01 vs 3,87 ± 0,90, p = 0,040; 3,49 ± 0,94, vs 3,83 ± 1,06, p = 0,020 respectively). In assessing the factors that had negative impact on the interest in participating in a clinical trial, the most significant were risk of side effects (3,01 ± 1,27), study of new medication (2,68 ± 1,21), and the risk of getting into the placebo group (2,64 ± 1,34) (so-called “objective” risk factors). At the same time, risk of side effects and risk of getting into the placebo group were also assessed at significantly lower score by group of patients that acquainted with IC together with the researcher (2,87 ± 1,28, vs 3,33 ± 1,17, p = 0,024; 2,51 ±1,25, vs 3,03 ± 1,34, p = 0,022 respectively). Furthermore, it was found that in the case of the researcher’s assistance acquaintance time with IC reduced threefold. We also evaluated the effect of the complexity of IC text on the decision-making process on participation in clinical trials. The group of respondents, who rated the IC as easy, appeared to be more interested in the final results of the study.Conclusion. Thus, when assessing the impact of the researcher on the review process of informed consent with the decision to participate in clinical trials, we found that in the case of assistance of the researcher, the acquaintance time with IC is reduced three times. In addition, this group of patients during the conversation with the researcher shows better and more clear understanding of the nature and general methodology of clinical trials, resulting in an adequate assessment “objective” risk factors for participation in clinical trials. Thus, this group of patients is more informed, compared with an “independent” group. According to the study “Face to Face”, we can recommend mandatory participation of a researcher during review process of the IC.https://bulletin.ssmu.ru/jour/article/view/663clinical trialsinformed consentdecision makingperceptionmotivationexpectations
spellingShingle O. I. Zvonareva
E. S. Kulikov
I. A. Deev
O. S. Kobyakova
O. S. Fedorova
N. A. Kirillova
E. A. Starovoytova
N. G. Zhukova
I. A. Zhukova
V. V. Esip
E. D. Schastnyy
N. V. Khurkhurova
L. Yu. Nikitina
T. S. Golosova
I. D. Pimenov
M. A. Netaeva
S. V. Fedosenko
Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
Бюллетень сибирской медицины
clinical trials
informed consent
decision making
perception
motivation
expectations
title Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
title_full Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
title_fullStr Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
title_full_unstemmed Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
title_short Role of Informed Consent in a Decision-making on Participation in The Clinical Trial: Multicenter study in Russia “Face to Face”
title_sort role of informed consent in a decision making on participation in the clinical trial multicenter study in russia face to face
topic clinical trials
informed consent
decision making
perception
motivation
expectations
url https://bulletin.ssmu.ru/jour/article/view/663
work_keys_str_mv AT oizvonareva roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT eskulikov roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT iadeev roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT oskobyakova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT osfedorova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT nakirillova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT eastarovoytova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT ngzhukova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT iazhukova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT vvesip roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT edschastnyy roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT nvkhurkhurova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT lyunikitina roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT tsgolosova roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT idpimenov roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT manetaeva roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface
AT svfedosenko roleofinformedconsentinadecisionmakingonparticipationintheclinicaltrialmulticenterstudyinrussiafacetoface